Sarepta Therapeutics Beats Q3 2026 Estimates as Revenue Falls 4.5% to $381.4M

Sarepta Therapeutics (SRPT) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $381.4 million, down 4.5% from a year earlier, above the $352.2 million estimate, and adjusted EPS was $0.13 above the $0.07 estimate.

Shares fell 6.1% in after-hours trading as of 4:08 p.m. ET, to $16.50 from a $17.57 close.

Q3 2026 scorecard

By our calculation, revenue was $29.1 million above the estimate and adjusted EPS was $0.06 above it. The QoQ column compares with the previous quarter's revenue of $401.3 million and adjusted EPS of -$0.05. The YoY column compares with $399.4 million and -$1.80 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 4 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 8 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $399.4 million, $442.9 million, $730.8 million, $401.3 million and $381.4 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$0.06 and revenue of $351.4 million next quarter, based on 7 analysts.
• Revenue growth. Whether revenue stabilizes after this quarter's 4.5% decline from a year earlier to $381.4 million.
• Estimate record. Whether Sarepta Therapeutics extends a record of beating EPS estimates in 4 of its last 8 reports.
• Related coverage. See our reports on Pulse Biosciences, Five9, Paylocity and ICU Medical.

Sources: Results are from Sarepta Therapeutics's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Sarepta Therapeutics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.